On Wednesday, Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) released its Environmental, Social and Governance (ESG) Report for calendar year 2020, describing the company’s commitment to sustain
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material.
As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company in the medical psychedelics space, announced it has received clearance from the U.S.
Cybin Inc. (NYSE: CYBN) a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA).